Identification of biological targets of therapeutic intervention for clear cell renal cell carcinoma based on bioinformatics approach

[1] Figlin RA(2015)Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma Expert Opin Biol Ther. 15 1241-1248

[2] Srinivasan R(2015)New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease Clin Cancer Res 21 10-17

[3] Ricketts CJ(2010)Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 v137-v139

[4] Sourbier C(2011)Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials BJU Int 108 1556-1563

[5] Linehan WM(2005)Renal-cell carcinoma N Engl J Med. 353 2477-2490

[6] Escudier B(2009)Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney Cancer Res 69 4674-4681

[7] Kataja V(2009)Treatment of kidney cancer Cancer 115 2262-2272

[8] Coppin C(2016)Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression J Urol 195 180-187

[9] Kollmannsberger C(2009)The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival J Urol 182 2144-2149

[10] Le L(2012)MicroRNAs in metabolism and metabolic disorders Nat Rev Mol Cell Biol 13 239-250

[1] Figlin RA(2015)Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma Expert Opin Biol Ther. 15 1241-1248

[2] Srinivasan R(2015)New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease Clin Cancer Res 21 10-17

[3] Ricketts CJ(2010)Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 v137-v139

[4] Sourbier C(2011)Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials BJU Int 108 1556-1563

[5] Linehan WM(2005)Renal-cell carcinoma N Engl J Med. 353 2477-2490

[6] Escudier B(2009)Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney Cancer Res 69 4674-4681

[7] Kataja V(2009)Treatment of kidney cancer Cancer 115 2262-2272

[8] Coppin C(2016)Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression J Urol 195 180-187

[9] Kollmannsberger C(2009)The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival J Urol 182 2144-2149

[10] Le L(2012)MicroRNAs in metabolism and metabolic disorders Nat Rev Mol Cell Biol 13 239-250